Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens

Oncologist

Volumn 19, Issue 6, 2014, Pages 639-644

  Khera, Nandita ^a   Emmert, Amy ^b   Storer, Barry E ^c   Sandmaier, Brenda M ^c   Alyea, Edwin P ^b   Lee, Stephanie J ^c  

^a MAYO CLINIC   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c USA   (United States)

Author keywords

Allogeneic transplantation; Costs; Economics; Hematopoietic stem cell transplantation

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CD45 ANTIGEN; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; COST BENEFIT ANALYSIS; FEBRILE NEUTROPENIA; HEALTH CARE COST; HUMAN; KARNOFSKY PERFORMANCE STATUS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; DISEASE FREE SURVIVAL; DONOR; ECONOMICS; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; PATHOLOGY;

AGED; BONE MARROW; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84901913358     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0406     Document Type: Article

References (24)

1. Ruutu T, Eriksson B, Remes K et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002;100:1977-1983.
2. McDonald GB, Slattery JT, Bouvier ME et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101:2043-2048.
3. Yokoe D, Casper C, Dubberke E et al. Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated. Bone Marrow Transplant 2009;44: 495-507.
4. Sorror ML, Sandmaier BM, Storer BE et al. Longterm outcomes among older patients following nonmyeloablative conditioningand allogeneic hematopoietic cell transplantation for advanced hematologicmalignancies. JAMA 2011;306:1874-1883.
5. Brunstein CG, Fuchs EJ, Carter SL et al. Alternative donor transplantation after reduced intensity conditioning: Results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011;118:282-288.
6. McClune BL, Weisdorf DJ, Pedersen TL et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010;28:1878-1887.
7. Mineishi S. Overcoming the age barrier in hematopoietic stem cell transplantation: Progress, but still a long way to go. JAMA 2011;306: 1918-1920.
8. Cordonnier C, Maury S, Esperou H et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant 2005; 36:649-654.
9. Saito AM, Zahrieh D, Cutler C et al. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant 2007;40:209-217.
10. Svahn BM, Alvin O, Ringdén O et al. Costs of allogeneic hematopoietic stem cell transplantation. Transplantation 2006;82:147-153.
11. Svahn BM, Remberger M, Alvin O et al. Increased costs after allogeneic haematopoietic SCT are associated with major complications and retransplantation. Bone Marrow Transplant 2012;47: 706-715.
12. Khera NSB, Storer B, Sandmaier BM et al. Costs of second allogeneic hematopoietic cell transplantation. Transplantation 2013;96:108-115.
13. Abou-Nassar KE, Kim HT, Blossom J et al. The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012;708-715.
14. Overview of BLS Statistics on Inflation and Prices. Available from http://www.bls.gov/bls/inflation.htm
15. Griffiths RI, Bass EB, Powe NR et al. Factors influencing third party payer costs for allogeneic BMT. Bone Marrow Transplant 1993;12:43-48.
16. Lee SJ, Klar N, Weeks JC et al. Predicting costs of stem-cell transplantation. J Clin Oncol 2000;18: 64-71.
17. Saito AM, Cutler C, Zahrieh D et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant 2008;14:197-207.
18. Majhail NS, Mau LW, Denzen EM et al. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: A study using a large national private claims database. Bone Marrow Transplant 2013;48:294-300.
19. Espérou H, Brunot A, Roudot-Thoraval F et al. Predicting the costs of allogeneic sibling stem-cell transplantation: Results from a prospective, multicenter, French study. Transplantation 2004;77: 1854-1858.
20. Alousi AM, Le-Rademacher J, Saliba RM et al. Who is the better donor for older hematopoietic transplant recipients: An older-aged sibling or a young, matched unrelated volunteer? Blood 2013;121:2567-2573.
21. Welch HG, Larson EB. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 1989;321:807-812.
22. Mielcarek M, Martin PJ, Leisenring W et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003;102:756-762.
23. Petersen SL, Madsen HO, Ryder LP et al. Haematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: Results, complications and admission requirements in a single institution. Br J Haematol 2004;125:225-231.
24. Rizzo JD, Vogelsang GB, Krumm S et al. Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? J Clin Oncol 1999;17:2811-2818.